Juillet Yves
Leem (Les Entreprises du Médicament) 88 rue de la Faisanderie 75016 Paris.
Bull Acad Natl Med. 2008 Oct;192(7):1423-34; discussion 1434-6.
Drug counterfeiting is a growing danger, and not only in developing countries where it can account for up to 40% of the market. Counterfeit drugs can be both ineffective and toxic. They are becoming more and more common in the USA and even in Europe. France seems to have escaped this problem for the time being. The drug distribution chain (producer-wholesaler-retail pharmacist) is both the gatekeeper and the weak point of the system. Counterfeiting is more frequent in countries where drug distribution is badly organized or excessively deregulated The increasing use of the Internet for self-diagnosis and self-medication is adding to the problem, particularly in countries where social security coverage is limited The IMPACT initiative, launched in 2006 by WHO and other stakeholders worldwide (health authorities, healthcare professionals, patients, customs, police, industry), is aimed at developing precise legislative, regulatory and technical measures, and at increasing global awareness of this threat to public health.
药品造假正成为日益严重的威胁，且不仅在发展中国家如此，在这些国家假药可占到市场的40%。假药可能既无疗效又有毒性。在美国乃至欧洲，假药正变得越来越普遍。法国目前似乎躲过了这一问题。药品分销链（生产商-批发商-零售药剂师）既是该体系的把关者，也是其薄弱环节。在药品分销组织不善或监管过度放松的国家，造假更为频繁。互联网用于自我诊断和自我药疗的日益增加也使问题更加严重，尤其是在社会保障覆盖有限的国家。由世界卫生组织及全球其他利益相关方（卫生当局、医疗保健专业人员、患者、海关、警方、行业）于2006年发起的“IMPACT倡议”，旨在制定精确的立法、监管和技术措施，并提高全球对这一公共卫生威胁的认识。
